MAPK Signaling
Research Areas
Products Related to MAPK Signaling(660)
- GC10069NSC 23766 trihydrochlorideCAS: 1177865-17-6Purity: >99.00%
NSC 23766 trihydrochloride is a selective Rac1 GTPase inhibitor that suppresses Rac1 activation by specifically blocking the guanine nucleotide exchange factors Trio and Tiam1, with an IC₅₀ of approximately 50μM for Rac1.
- GC10941cAMPS-Rp, triethylammonium saltCAS: 151837-09-1Purity: >99.00%
cAMPS-Rp, triethylammonium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (Kis of 12.5 μM and 4.5 μM, respectively) antagonist.
- GC11599B-Raf inhibitor 1CAS: 1093100-40-3Purity: >98.00%
B-Raf inhibitor 1 is a potent Raf kinase inhibitor with Kis of 1 nM, 1 nM, and 0.3 nM for B-RafWT, B-RafV600E, and C-Raf, respectively.
- GC12706cAMPS-Sp, triethylammonium saltCAS: 73208-40-9Purity: >98%
cAMPS-Sp, triethylammonium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (Kis of 12.5 μM and 4.5 μM, respectively) antagonist.
- GC12824Dibutyryl-cAMP, sodium saltCAS: 16980-89-5Purity: >99.00%
Dibutyryl-cAMP, sodium salt, also known as Bucladesine, is a cell-permeable cyclic nucleotide analogue which mimics the action of endogenous cAMP and acts as a phosphodiesterase inhibitor.
- GC12843MEK162 (ARRY-162, ARRY-438162)CAS: 606143-89-9Purity: >99.50%
MEK162 (ARRY-162, ARRY-438162) (MEK162) is an oral and selective MEK1/2 inhibitor. MEK162 (ARRY-162, ARRY-438162) (MEK162) inhibits MEK with an IC50 of 12 nM.
- GC14907B-Raf inhibitor 1 dihydrochlorideCAS: 1191385-19-9Purity: >98%
B-B-Raf inhibitor 1 dihydrochloride is a potent Raf kinase inhibitor with Kis of 1 nM, 1 nM, and 0.3 nM for B-RafWT, B-RafV600E, and C-Raf, respectively.
- GC15187Dabrafenib (GSK2118436)CAS: 1195765-45-7Purity: >99.50%
Dabrafenib (GSK2118436) is a potent, selective, and efficacious inhibitor of B-Raf V600E , with therapeutic efficacy against tumors harboring activating B‑Raf mutations.
- GC15525cGMP Dependent Kinase Inhibitor PeptideCAS: 82801-73-8Purity: >98.00%
cGMP Dependent Kinase Inhibitor Peptide is an ATP-competitive inhibitor of cGMP-dependent protein kinase (PKG), with a Ki of 86 μM.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC10030 | EHop-016 | 1380432-32-5 | >99.00% | |
EHop-016 is a potent inhibitor of Rac GTPase Rac1, with an IC 50 value of 1.1μM. | ||||
| GC10069 | NSC 23766 trihydrochloride | 1177865-17-6 | >99.00% | |
NSC 23766 trihydrochloride is a selective Rac1 GTPase inhibitor that suppresses Rac1 activation by specifically blocking the guanine nucleotide exchange factors Trio and Tiam1, with an IC₅₀ of approximately 50μM for Rac1. | ||||
| GC10110 | PD318088 | 391210-00-7 | >99.50% | |
Allosteric MEK1/2 inhibitor, non-ATP competitive | ||||
| GC10693 | c-JUN peptide | 610273-01-3 | >98% | |
JNK/c-Jun interaction inhibitor | ||||
| GC10941 | cAMPS-Rp, triethylammonium salt | 151837-09-1 | >99.00% | |
cAMPS-Rp, triethylammonium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (Kis of 12.5 μM and 4.5 μM, respectively) antagonist. | ||||
| GC11599 | B-Raf inhibitor 1 | 1093100-40-3 | >98.00% | |
B-Raf inhibitor 1 is a potent Raf kinase inhibitor with Kis of 1 nM, 1 nM, and 0.3 nM for B-RafWT, B-RafV600E, and C-Raf, respectively. | ||||
| GC11685 | GW5074 | 220904-83-6 | >99.00% | |
GW5074 is a potent and selective c-Raf inhibitor (IC 50 =9nM). | ||||
| GC11890 | SB590885 | 405554-55-4 | >98.00% | |
Potent B-Raf inhibitor | ||||
| GC12706 | cAMPS-Sp, triethylammonium salt | 73208-40-9 | >98% | |
cAMPS-Sp, triethylammonium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (Kis of 12.5 μM and 4.5 μM, respectively) antagonist. | ||||
| GC12819 | PD98059 | 167869-21-8 | >98.00% | |
PD98059 is a potent and selective MEK inhibitor with an IC 50 of 2 μM. | ||||
| GC12824 | Dibutyryl-cAMP, sodium salt | 16980-89-5 | >99.00% | |
Dibutyryl-cAMP, sodium salt, also known as Bucladesine, is a cell-permeable cyclic nucleotide analogue which mimics the action of endogenous cAMP and acts as a phosphodiesterase inhibitor. | ||||
| GC12843 | MEK162 (ARRY-162, ARRY-438162) | 606143-89-9 | >99.50% | |
MEK162 (ARRY-162, ARRY-438162) (MEK162) is an oral and selective MEK1/2 inhibitor. MEK162 (ARRY-162, ARRY-438162) (MEK162) inhibits MEK with an IC50 of 12 nM. | ||||
| GC12926 | VX-745 | 209410-46-8 | >98.00% | |
VX-745 (VX-745) is a potent, blood-brain barrier penetrant, highly selective inhibitor of p38α inhibitor with an IC50 for p38α of 10 nM and for p38β of 220 nM. | ||||
| GC12970 | Furosemide | 54-31-9 | >98.00% | |
GABAA receptors antagonist | ||||
| GC13286 | ZM336372 | 208260-29-1 | >98% | |
C-Raf inhibitor, potent and selective | ||||
| GC13468 | BI-D1870 | 501437-28-1 | >98.00% | |
P90 RSK inhibitor,ATP-competitive and cell-permeable | ||||
| GC14643 | AZD8330 | 869357-68-6 | >99.00% | |
MEK 1/2 inhibitor | ||||
| GC14907 | B-Raf inhibitor 1 dihydrochloride | 1191385-19-9 | >98% | |
B-B-Raf inhibitor 1 dihydrochloride is a potent Raf kinase inhibitor with Kis of 1 nM, 1 nM, and 0.3 nM for B-RafWT, B-RafV600E, and C-Raf, respectively. | ||||
| GC15055 | AZ 628 | 878739-06-1 | >99.50% | |
Raf kinases,potent and ATP-competitive | ||||
| GC15187 | Dabrafenib (GSK2118436) | 1195765-45-7 | >99.50% | |
Dabrafenib (GSK2118436) is a potent, selective, and efficacious inhibitor of B-Raf V600E , with therapeutic efficacy against tumors harboring activating B‑Raf mutations. | ||||
| GC15359 | SL-327 | 305350-87-2 | >98.00% | |
SL-327 is a selective inhibitor of MEK1 and MEK2, with IC 50 values of 0.18μM and 0.22μM, respectively. | ||||
| GC15524 | Bumetanide | 28395-03-1 | >99.50% | |
NKCC cotransporter inhibitor | ||||
| GC15525 | cGMP Dependent Kinase Inhibitor Peptide | 82801-73-8 | >98.00% | |
cGMP Dependent Kinase Inhibitor Peptide is an ATP-competitive inhibitor of cGMP-dependent protein kinase (PKG), with a Ki of 86 μM. | ||||
| GC15821 | PF-04880594 | 1111636-35-1 | >98% | |
RAF inhibitor | ||||
